Results Recap: Medtronic Highlights Data To Contrast With Recent Meta-Analysis That Sparked Drug-Coated Balloon Scrutiny
Executive Summary
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from MedDeviceTracker, includes medical device trial results announced from Jan. 11 through Jan. 24. This week's list is dominated by results presentations from the Leipzig Interventional Course (LINC) in Leipzig, Germany, including trials of devices from Medtronic, Boston Scientific, Gore, Profusa, InspireMD, and Vessi.
You may also be interested in...
FDA Approves Boston Scientific’s Vici Venous Iliac Stent
The US FDA approval of Boston Scientific's Vici venous stent is based on VIRTUS trial results which met the prespecified performance goal for primary patency after one year.
Pivotal Trial Of Carmat’s Total Artificial Heart Delayed
Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.
2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott
Reported sales and earnings from the publicly traded cardiovascular device companies in 2018 were generally strong, led by transcatheter aortic valve replacement devices, but some sectors of the industry, especially ventricular assist devices and peripheral drug-coated balloons, face significant challenges. Here's a recap of results from the cardio device companies that have reported so far, with a focus on Medtronic, Edwards, and Abbott.